{"analyses":[{"ciLowerLimit":"2.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"140.93","groupDescription":"Indicated significance at the 5% (two-sided) level of significance","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"17.96","statisticalComment":"The proportion of participants achieving platelet counts \\>=50 Gi/L for those participants receiving eltrombopag versus placebo was compared.","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Participants who achieved a platelet count \\>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.","groups":[{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kilograms (kg) received placebo 37.5 milligrams (mg) once daily (QD), and those with a body weight \\>=27 kg received placebo 50 mg QD. Participants of East Asian ancestry received a starting dose of placebo 25 mg QD. Participants aged between 1 and 5 years received placebo 1.2 milligrams per kilogram (mg/kg) QD; participants of East Asian ancestry received a starting dose of placebo 0.8 milligrams per kilograms per day (mg/kg/day).","id":"OG000","title":"Part 1 (Randomized Period)- Placebo"},{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG001","title":"Part 1 (Randomized Period)-Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants. The ITT Population was the primary population used for assessing efficacy.","reportingStatus":"POSTED","timeFrame":"From Week 5 up to Week 12 of Part 1","title":"Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1","type":"PRIMARY","unitOfMeasure":"Participants"}